.
@ireneghobrial
ID: 452461489
01-01-2012 21:45:18
5,5K Tweet
7,7K Takipçi
0 Takip Edilen
Congratulations to Dr Marcela Maus, MD, PhD, and @SRBailey32, PhD, et al., recipients of this year’s Blood Cancer Discovery Award for Outstanding Journal Article! Learn more about this award: bit.ly/45ugQfQ Mass General Cancer Center Harvard Medical School
Join us in #Boston! Don't miss the chance to listen and ask questions to #myeloma specialists from Dana-Farber: . , Catherine Marinac, PhD, Omar Nadeem and Elizabeth (Betsy) O'Donnell, MD. Register here: buff.ly/3Xtm7kA
Hi #MedTwitter! I'm Annie, MS4 Mayo Clinic Alix School of Medicine and I am pumped to be applying #IM for #Match2024! I am passionate about #hemeonc 🩸, #palliative 🫂 , & #research 🔬 - if you can't find me running stats on an #mmsm trial or rounding in the ICU, I'm probably playing soccer ⚽
As always, stellar work by nizar jacques bahlis and team. This is key to understanding resistance to T-cell therapies based on the integrity (or lack) of the target (BCMA or GPRC5D). Consistent with clonal selection. Superb science in Nature Medicine. Kudos! 👏 #mmsm #MedTwitter
BREAKING NEWS! Nature Medicine study shows mechanisms of resistance to BCMA- or GPRC5D-targeted immunotherapies in myeloma #mmsm@hollyleeYJ Francesco Maura nizar jacques bahlis International Myeloma Foundation Multiple Myeloma RF @HealthtreeMM Sylvester Comprehensive Cancer Center nature.com/articles/s4159…
Carl June on The #Boundless #Potential of #CAR_T Cell Therapy Society for Immunotherapy of Cancer AACR ASCO pennmedicine.org/news/news-blog… via Penn Medicine
Exciting preprint to share! With Diko Kazandjian, C. Ola Landgren, M.D. , Francesco Maura. Genomic profiling of high-risk smoldering multiple myeloma (HR-SMM) to contextualize the generally favorable results in trials of early tx intervention. tinyurl.com/2c58vmza #mmsm (1/n)
Thanks for reading! Big thanks to everyone who made this possible including Diko Kazandjian C. Ola Landgren, M.D. @francescomaura4 of Sylvester Comprehensive Cancer Center Patrick Blaney Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Faith E Davies Gareth Morgan and the ADuong team . Gad Getz Laboratory Romanos SP (16/16)
Check out our latest preprint paper: Novel insights on how genomic profiling of high-risk smoldering multiple myeloma patients influences treatment outcomes. Better profiling is urgently needed! #mmsm International Myeloma Foundation Multiple Myeloma RF @HealthtreeMM Sylvester Comprehensive Cancer Center ASH The Leukemia & Lymphoma Society
Investigators in multiple myeloma discussed new therapies, optimal sequencing, the role of MRD, CAR T-cell therapy & more! Dana-Farber Winship Cancer Institute of Emory University Stanford Cancer Institute MD Anderson Cancer Center . Surbhi Sidana, MD Krina Patel ow.ly/KjP450PG3Jy
📣 BREAKING NEWS 📣 We're excited to announce the 12 teams shortlisted for a #CancerGrandChallenges award. Each team has the chance to receive up to $25m to make radical progress against cancer’s toughest challenges. Discover the teams: bit.ly/3YYV5lS National Cancer Institute Cancer Research UK
📢Clonal hematopoiesis driven by mCAs📢What fitness effects do mCAs confer to our blood cells?🩸 How often do they occur? Does an mCA’s fitness correlate with blood cancer risk?🔎Read mine & Jamie Blundell's latest paper Nature Genetics to find out (& more!):👉🔗rdcu.be/dlRRr